جارٍ التحقق…
تُرجمت تلقائيًا. للجرعات والتحذيرات: راجع النص الأصلي بالإنجليزية. اقرأ بالإنجليزية

Tonex-G Cream

NAFDAC Reg. No. A11-100253 · Drug

Registered with NAFDAC. Registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Tonex-G Cream
رقم NAFDAC
A11-100253
المادة الفعالة
Triamcinolone; Econazole; Gentamicin
التركيز
0.05%; 0.5%; 0.05%
الشكل
كريمي
Manufacturer
Not listed
Applicant (holder)
Evergreen Morning Star Pharmaceutical Ind. Ltd
Approved
2 Dec 2021
الحالة
Active View on NAFDAC ↗
التسجيل ساري حتى
1 Dec 2026
تنبيهات منظمة الصحة العالمية
None found
Community reports
None
Times checked
0

About the medicine: Triamcinolone: uses, dosage and brands worldwide

What we found

  • Tonex-G Cream is on the NAFDAC register with an active registration (A11-100253). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Tonex-G Cream

ما تقوله النشرة الرسمية. إذا وصفه لك طبيب، فاتبع الوصفة. وإذا اختلفت نشرة عبوتك، فالأولوية لها.

لمن هو

Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

كيف يُتناول وكم مرة
  • Apply a thin film of Triamcinolone Acetonide Ointment 0.025% to the affected area two to four times daily
  • Apply a thin film of the 0.1% or the 0.5% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily
  • Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions
  • Apply a thin film of ointment to the lesion, cover with a pliable nonporous film, and seal the edges
  • If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication
  • The frequency of changing dressings is best determined on an individual basis
  • It may be convenient to apply Triamcinolone Acetonide Ointment under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion)
  • When utilizing the 12-hour occlusion regimen, additional ointment should be applied, without occlusion, during the day
  • Reapplication is essential at each dressing change
  • If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted
Children
  • Pediatric patients may demonstrate greater susceptibility to topical corticosteroid induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio
  • HPA axis suppression, Cushing’s syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids
  • Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. …
While you are taking it
  • Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1
  • This medication is to be used as directed by the physician
  • It is for external use only
  • Avoid contact with the eyes. 2
  • Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3
  • The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4
  • Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. …
Talk to a doctor first if

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Warnings

PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. …

الآثار الجانبية المحتملة

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Pregnancy and breastfeeding

Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on the teratogenic effects from topically applied corticosteroids. …

If you take too much

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ).

إذا نسيت جرعة

تناولها عندما تتذكر، إلا إذا اقترب موعد الجرعة التالية. عندها تخطَّ الجرعة المنسية. لا تتناول جرعتين معًا أبدًا للتعويض. راجع النشرة، فبعض الأدوية مختلفة.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-20.

Label for triamcinolone and econazole and gentamicin, the active ingredient registered with NAFDAC.

Check your pack of Tonex-G Cream

Add the expiry date on your pack for a full Trust Score.

أو التقط صورًا للعبوة
تبقّت 3 عمليات تحقق مجانية اليوم Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Tonex-G Cream

What is in Tonex-G Cream?

Tonex-G Cream contains Triamcinolone; Econazole; Gentamicin (0.05%; 0.5%; 0.05%), as cream, according to its NAFDAC registration record.

Is Tonex-G Cream registered with NAFDAC?

Yes. Tonex-G Cream is listed on the NAFDAC register under registration number A11-100253, and its registration is active as of 5 November 2026.

Has Tonex-G Cream been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Tonex-G Cream in our automatically synced alert list.

How can I check that my pack of Tonex-G Cream is genuine?

Run a free authenticity scan with the NAFDAC number A11-100253, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Tonex-G Cream?

Follow your prescription or the leaflet in your pack. The official label says: Apply a thin film of Triamcinolone Acetonide Ointment 0.025% to the affected area two to four times daily. Apply a thin film of the 0.1% or the 0.5% Triamcinolone Acetonide Ointment, as appropriate, to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply a…

What is Tonex-G Cream used for?

Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. (Summarised from the official U.S. FDA label for triamcinolone and econazole and gentamicin. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Tonex-G Cream? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.